A phase 2 trial of enGene's detalimogene voraplasmid in non-muscle invasive bladder cancer (NMIBC) has delivered a positive result, setting it on course for a filing with the FDA next year. The LEGEND ...
Commercial content notice: Taking one of the bookmaker offers featured in this article may result in a payment to The Sun. 18+. T&Cs apply. GambleAware.org FOR some of you, checking your accumulator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback